looking forward to the qtrly!, page-7

so apart from the technicals, a brief perusal of the investor update from november last year shows this:

* revenue up 20% yoy at $8.8m
* losses pared
* cash at hand
* oem business strengthened (medivet, terumo, fres kabi)
* ramp up new supply contracts and oem activities
* global supply chain
* large revenue in first quarter
* master distribution for medivet in uk
* 442m shares with top 20 holding 62.8%
* blue chip customers
* major growth platform in supply chain
* specialist manufacturer of oem products
* targeting global market
* aussie market <1% of global market, sales of A$4.75b
* international growth is now underway
* revenue from o'seas markets starting to kick in
* future growth requires no capex
* dr geoff cummings onboard as director

what more do you need?